Decatur, GA 30033
Randomized, double-blind, placebo-controlled, parallel-group, 18-month safety and
Efficacy study of Leuco-methylthioninium bis(hydromethanesulfonate) in subjects with
mild Alzheimer’s disease.
Mild to moderate Alzheimer's disease or memory loss.
The TOMMORROW study seeks to learn more about the genetic risk for developing mild cognitive impairment due to Alzheimer’s disease (MCI due to AD) and whether an investigational medication might prov...
New York, NY 10128
Sherman Oaks, CA 91316
Are you beginning to experience a decline in your memory and thinking skills?
California Neuroscience Research is conducting a research study on dementia caused by early Alzheim...
St. Louis, MO 63141
Ocala, FL 34471
The study is for individuals with Alzheimer's Disease or mild cognitive impairment due to Alzheimer's Disease. The study lasts 18 months with an optional 24 month long-term extension. The study inc...
Berlin, NJ 08009
Hassman Research Institute is conducting a clinical research study for men and women who have mild to moderate Alzheimer's Disease or Memory loss, Doctors are studying a new investigational medicatio...
NeuroStudies.net is conducting a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzhe...
Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers...
| All trademarks are property of their legal owners. | All Rights Reserved
ClinicalConnection.com is a resource that provides information on clinical trials conducted worldwide.
ClinicalConnection.com does not conduct or endorse clinical trials. Please consult your physician before participating.
© All Rights Reserved.
Terms of Service